In addition to native EVs, bioengineered EVs bearing therapeutic payloads such as dopamine, catalase, or α-synuclein-targeting siRNA demonstrated enhanced activity in preclinical models of PD [154]. This evidence concerns the gene SNCA and Parkinson disease.